All News

6 December 2010

Phase III Study Showed Rituxan for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood CancerAntibodies

6 December 2010

Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual MeetingAntibodies

6 December 2010

Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology MeetingAntibodies

6 December 2010

Long-Term Follow-Up Data from Phase 2 Study Show Micromet’s Blinatumomab Produces Durable Remissions in Patients with Acute Lymphoblastic LeukemiaAntibodies

6 December 2010

Micromet’s Blinatumomab Produces High Objective Response Rate in Spectrum of Relapsed Non-Hodgkin’s Lymphoma PatientsAntibodies

6 December 2010

Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual MeetingAntibodies

6 December 2010

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Subcutaneous Formulation of ORENCIA (abatacept) for Adult Patients with Moderate to Severe Rheumatoid ArthritisAntibodies

6 December 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA EXTENSION OF BENLYSTA PDUFA TARGET DATE TO MARCH 10, 2011Antibodies

2 December 2010

MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic LeukemiaAntibodies

1 December 2010

Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial in Liver CancerAntibodies

1 December 2010

Tolerx and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer TreatmentAntibodies

30 November 2010

ImmunoGen, Inc. Announces Initiation of Randomized Clinical Trial Evaluating IMGN901 for First-Line Treatment of Small-Cell Lung CancerAntibodies

29 November 2010

Thallion and LFB Initiate Phase II SHIGATEC TrialAntibodies

24 November 2010

Innate Pharma Initiation of a Phase II Clinical Trial with Anti-KIR Monoclonal Antibody IPH 2101 in Smoldering Myeloma PatientsAntibodies

22 November 2010

Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical SignificanceAntibodies

22 November 2010

Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular DegenerationAntibodies

22 November 2010

f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic AntibodiesAntibodies

19 November 2010

FDA Approves Amgen’s XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid TumorsAntibodies

19 November 2010

ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for IMGN388 at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAntibodies

18 November 2010

Stromedix Expands its Fibrosis Pipeline Through In-Licensing Agreement with UCSFAntibodies

18 November 2010

Curis Presents CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at 22nd EORTC-NCI-AACR SymposiumAntibodies

17 November 2010

Morphotek, Inc. Announces Initiation of a Sponsored Research Agreement (SRA) with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic CancerAntibodies

17 November 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE VOTE OF FDA ADVISORY COMMITTEE TO RECOMMEND APPROVAL OF BENLYSTA FOR SYSTEMIC LUPUS ERYTHEMATOSUSAntibodies

17 November 2010

Peregrine’s Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection ModelsAntibodies

16 November 2010

Anthera Pharmaceuticals, Inc. (ANTH) Suspends Enrollment and Dosing in PEARL-SC Clinical Trial to Address Reports of Vial ProblemsAntibodies

16 November 2010

ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune DiseasesAntibodies

15 November 2010

BioWa Announces License of POTELLIGENT Technology to AgensysAntibodies

11 November 2010

Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic ArthritisAntibodies

10 November 2010

BioInvent Announces Approval to Start Phase II Trial for Its Novel Cardiovascular Drug BI-204Antibodies

10 November 2010

Positive XOMA 052 Results in Inflammatory Eye Disease – Behcet’s Uveitis – Presented at American College of Rheumatology Scientific MeetingAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Report Package: “Drug the Undruggable” Technologies

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Bispecific Antibodies for Immuno-Oncology & Other Diseases